leflunomide has been researched along with Eczema, Atopic in 7 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A subgroup of atopic eczema patients requires systemic immunomodulatory treatment for long time periods." | 2.44 | Novel immunological approaches in the treatment of atopic eczema. ( Andres, C; Belloni, B; Mempel, M; Ollert, M; Ring, J, 2008) |
| "Atopic dermatitis is a chronically relapsing eczematous disease of the skin." | 2.44 | Emerging treatment of atopic dermatitis. ( Hsu, CJ; Wang, LF, 2007) |
| "Atopic dermatitis is a common inflammatory skin condition with increasing incidence in recent decades." | 2.43 | Recent developments in the treatment of adult atopic dermatitis. ( Barnetson, RS; Pua, VS, 2006) |
| "Leflunomide is an immunomodulating and disease-modifying antirheumatic drug with anti-inflammatory and immunosuppressive activity, exhibiting an extremely long in vivo half life." | 2.43 | Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. ( Pfeiffer, C; Vitéz, L; Wozel, G, 2006) |
| "Leflunomide is a pyrimidine de novo synthesis-inhibiting immunosuppressant exhibiting an extremely long in vivo half life of its active metabolite." | 1.32 | Leflunomide as a novel treatment option in severe atopic dermatitis. ( Pfeiffer, C; Schmitt, J; Wozel, G, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmitt, J | 2 |
| Abraham, S | 1 |
| Trautmann, F | 1 |
| Stephan, V | 1 |
| Fölster-Holst, R | 1 |
| Homey, B | 1 |
| Bieber, T | 1 |
| Novak, N | 1 |
| Sticherling, M | 1 |
| Augustin, M | 1 |
| Kleinheinz, A | 1 |
| Elsner, P | 1 |
| Weidinger, S | 1 |
| Werfel, T | 1 |
| Belloni, B | 1 |
| Andres, C | 1 |
| Ollert, M | 1 |
| Ring, J | 1 |
| Mempel, M | 1 |
| Wozel, G | 2 |
| Pfeiffer, C | 2 |
| Kagami, S | 1 |
| Saeki, H | 1 |
| Komine, M | 1 |
| Kakinuma, T | 1 |
| Tsunemi, Y | 1 |
| Nakamura, K | 1 |
| Sasaki, K | 1 |
| Asahina, A | 1 |
| Tamaki, K | 1 |
| Pua, VS | 1 |
| Barnetson, RS | 1 |
| Vitéz, L | 1 |
| Hsu, CJ | 1 |
| Wang, LF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis[NCT00931242] | Phase 2 | 10 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score. (NCT00931242)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Apremilast | 2 |
EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score. (NCT00931242)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Apremilast | 1 |
Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale, with 0 being no disease activity and 5 being maximum disease activity, at week 12 (NCT00931242)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Apremilast | 2 |
4 reviews available for leflunomide and Eczema, Atopic
| Article | Year |
|---|---|
Novel immunological approaches in the treatment of atopic eczema.
Topics: Adult; Antibodies, Monoclonal; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic | 2008 |
Recent developments in the treatment of adult atopic dermatitis.
Topics: Antibodies, Monoclonal; Calcineurin Inhibitors; Dermatitis, Atopic; Humans; Immunoglobulins, Intrave | 2006 |
Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data.
Topics: Adult; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Severity | 2006 |
Emerging treatment of atopic dermatitis.
Topics: Androstadienes; Animals; Dermatitis, Atopic; Desensitization, Immunologic; Fluticasone; Histamine H1 | 2007 |
3 other studies available for leflunomide and Eczema, Atopic
| Article | Year |
|---|---|
Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
Topics: Adult; Alitretinoin; Anti-Inflammatory Agents; Azathioprine; Cyclosporine; Dermatitis, Atopic; Femal | 2017 |
Leflunomide as a novel treatment option in severe atopic dermatitis.
Topics: Acute Disease; Adult; Dermatitis, Atopic; Drug Administration Schedule; Humans; Immunosuppressive Ag | 2004 |
Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells.
Topics: Cell Line, Tumor; Cell Movement; Chemokine CCL26; Chemokines, CC; Culture Media, Conditioned; Dermat | 2005 |